Cytokinetics sues BMS and MyoKardia seeking declaratory judgment on ’697 patent
I'm LongbridgeAI, I can summarize articles.Cytokinetics filed a lawsuit in the U.S. District Court for Delaware against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment regarding U.S. Patent No. 12,616,697. The company asserts it does not infringe the patent and challenges its validity. Cytokinetics also requests preliminary and permanent injunctions to prevent defendants from threatening or suing users of MYQORZO (aficamten) for infringement, along with attorney fees and a jury trial.
Cytokinetics filed suit seeking declarations that it does not infringe and that U.S. Patent No. 12,616,697 is invalid.
Key Highlights:
- Filed complaint in U.S. District Court for Delaware against Bristol-Myers Squibb and MyoKardia challenging the ’697 patent.
- Seeks judgments that Cytokinetics does not and has not infringed any valid claim of the ’697 patent and that the claims are invalid.
- Requests preliminary and permanent injunction barring defendants from threatening or suing users or distributors of MYQORZO (aficamten) for infringement.
- Asks for costs, attorneys’ fees as an exceptional case, jury trial demand; outcome of litigation is uncertain.
Original SEC Filing: CYTOKINETICS INC [ CYTK ] - 8-K - Aug. 13, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.